ES2194205T3 - Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba. - Google Patents

Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.

Info

Publication number
ES2194205T3
ES2194205T3 ES97931960T ES97931960T ES2194205T3 ES 2194205 T3 ES2194205 T3 ES 2194205T3 ES 97931960 T ES97931960 T ES 97931960T ES 97931960 T ES97931960 T ES 97931960T ES 2194205 T3 ES2194205 T3 ES 2194205T3
Authority
ES
Spain
Prior art keywords
derivatives
triazolo
substituted
piridazina
ligandos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97931960T
Other languages
English (en)
Inventor
Howard Barff Broughton
William Robert Carling
Pineiro Jose Luis Castro
Alexander Richard Guiblin
Andrew Madin
Kevin William Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615645.0A external-priority patent/GB9615645D0/en
Priority claimed from GBGB9625397.6A external-priority patent/GB9625397D0/en
Priority claimed from GBGB9714420.8A external-priority patent/GB9714420D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2194205T3 publication Critical patent/ES2194205T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE DERIVADOS DE LA 1,2,4 - TRIAZOLO [4,3 - B] PIRIDAZINA SUSTITUIDOS O UNIDOS A ANILLOS 7,8. DICHOS DERIVADOS POSEEN UN SUSTITUYENTE HETEROARILO, FENILO O CICLOALQUILO SUSTITUIDO OPCIONALMENTE EN LA POSICION 3 Y UNA FRACCION ALCOXI SUSTITUIDA EN LA POSICION 6. DICHOS DERIVADOS SON LIGANDOS SELECTIVOS PARA LOS RECEPTORES GABA A , EN PARTICULAR, POSEEN ALTA AFINIDAD POR LAS SUBUNI DADES AL 2 Y/O AL 3 DE DICHOS RECEPTORES. DICHOS DERIVADOS SON POR CONSIGUIENTE UTILES EN EL TRATAMIENTO Y/O PREVENCION DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, INCLUYENDO LA ANSIEDAD Y LAS CONVULSIONES.
ES97931960T 1996-07-25 1997-07-17 Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba. Expired - Lifetime ES2194205T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9615645.0A GB9615645D0 (en) 1996-07-25 1996-07-25 Therapeutic agents
GBGB9625397.6A GB9625397D0 (en) 1996-12-06 1996-12-06 Therapeutic agents
GBGB9714420.8A GB9714420D0 (en) 1997-07-09 1997-07-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2194205T3 true ES2194205T3 (es) 2003-11-16

Family

ID=27268403

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97931960T Expired - Lifetime ES2194205T3 (es) 1996-07-25 1997-07-17 Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.

Country Status (24)

Country Link
US (1) US6255305B1 (es)
EP (1) EP0915875B1 (es)
JP (1) JP4216905B2 (es)
KR (1) KR20000029548A (es)
CN (1) CN1251589A (es)
AT (1) ATE236904T1 (es)
AU (1) AU723098B2 (es)
BG (1) BG103112A (es)
BR (1) BR9710729A (es)
CZ (1) CZ18199A3 (es)
DE (1) DE69720732T2 (es)
EA (1) EA002436B1 (es)
EE (1) EE9900027A (es)
ES (1) ES2194205T3 (es)
HU (1) HUP0600527A2 (es)
IL (1) IL127911A0 (es)
IS (1) IS4949A (es)
NO (1) NO990304L (es)
NZ (1) NZ333768A (es)
PL (1) PL331072A1 (es)
SK (1) SK9399A3 (es)
TR (1) TR199900047T2 (es)
WO (1) WO1998004559A2 (es)
YU (1) YU2899A (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69807074T2 (de) * 1997-05-08 2003-04-03 Merck Sharp & Dohme Substituierte 1,2,4-triazolo[3,4,-a]phthalazin-derivate als gaba-alpha 5-liganden
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
GB9718254D0 (en) 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) * 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
AU1041599A (en) * 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
GB9726699D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
GB9723999D0 (en) 1997-11-13 1998-01-14 Merck Sharp & Dohme Therapeutic use
GB9726701D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
GB9726702D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
US6110915A (en) * 1997-12-18 2000-08-29 Merck & Co., Inc. Antiemetic use of triazolo-pyridazine derivatives
JP2002509150A (ja) * 1998-01-14 2002-03-26 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのトリアゾロピリダジン誘導体
GB9801234D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801202D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801210D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
YU43800A (sh) * 1998-01-21 2002-12-10 Merck Sharp & Dohme Limited Triazolo-piridazin derivati kao ligandi za gaba receptore
GB9801397D0 (en) * 1998-01-22 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9813006D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Therapeutic agents
EP1087968A1 (en) * 1998-06-16 2001-04-04 MERCK SHARP & DOHME LTD. Triazolo-pyridine derivatives as ligands for gaba receptors
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
WO2000020417A1 (fr) * 1998-10-06 2000-04-13 Takeda Chemical Industries, Ltd. Composes de pyridazine condenses, leur procede de preparation et leur utilisation
AU760688B2 (en) 1998-10-16 2003-05-22 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for GABA receptors
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB2345443A (en) * 1999-01-08 2000-07-12 Merck Sharp & Dohme Use of triazolo-pyridazines for treating premenstrual syndrome
US6500828B1 (en) * 1999-01-27 2002-12-31 Merck Sharp & Dohme Ltd. Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
US6737242B1 (en) 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
GB9919957D0 (en) * 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
GB9921351D0 (en) * 1999-09-09 1999-11-10 Merck Sharp & Dohme Therapeutic agents
US6355638B1 (en) * 1999-11-25 2002-03-12 Merck Sharp & Dohme Ltd. Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929685D0 (en) * 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0000564D0 (en) 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
GB0008696D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
AU2002251266A1 (en) * 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002307163B2 (en) * 2001-04-10 2006-06-29 Merck & Co., Inc. A method of treating cancer
GB0122696D0 (en) 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
EP1496981A2 (en) * 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
CA2495285A1 (en) * 2002-08-13 2004-02-19 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7268136B2 (en) * 2002-12-18 2007-09-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
PL1697371T3 (pl) 2003-12-19 2007-09-28 Bristol Myers Squibb Co Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
DE602005021894D1 (de) * 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US7671050B2 (en) 2005-01-05 2010-03-02 Nycomed Gmbh Triazolophthalazines
ES2397080T3 (es) 2005-01-05 2013-03-04 Nycomed Gmbh Triazoloftalazinas como agentes inhibidores de la PDE2
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
EP2288612B1 (en) * 2008-04-04 2015-07-29 Gabather AB Gabaa receptor modulators
ES2451542T3 (es) 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
ES2603931T3 (es) * 2012-11-07 2017-03-02 F. Hoffmann-La Roche Ag Compuestos de triazolo
EP3407886A1 (en) * 2016-01-27 2018-12-05 Universität Zürich Use of gabaa receptor modulators for treatment of itch
CN107344936B (zh) * 2016-05-06 2022-06-03 上海赛默罗生物科技有限公司 三唑哒嗪类衍生物、其制备方法、药物组合物和用途
CN107344938B (zh) * 2016-05-06 2022-05-06 上海赛默罗生物科技有限公司 吡唑-三嗪类衍生物、其制备方法、药物组合物和用途
CN109862896A (zh) 2016-08-03 2019-06-07 西玛贝医药公司 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
WO2019226820A1 (en) 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
AU2020369597A1 (en) * 2019-10-23 2022-05-12 Neurocycle Therapeutics, Inc. Treatment of epileptic conditions with GABAA receptor modulators
WO2023150377A1 (en) * 2022-02-07 2023-08-10 The Regents Of The University Of Colorado, A Body Corporate Small molecule cxcr4 agonists, method of synthesis, and method of use
CN114591352B (zh) * 2022-05-11 2022-09-09 上海赛默罗生物科技有限公司 一种三唑并哒嗪类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1080712A (en) 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
FI81350C (fi) * 1982-01-18 1990-10-10 Lepetit Spa Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat.
US4487930A (en) 1982-09-07 1984-12-11 The Dow Chemical Company 6-[(Cyclic amino)alkylamino]-tetrahydrotriazolo[3,4-a]phthalazines
IT1194310B (it) 1983-07-12 1988-09-14 Lepetit Spa Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
FR2562071B1 (fr) * 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
GB9726702D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use

Also Published As

Publication number Publication date
EE9900027A (et) 1999-08-16
YU2899A (sh) 2000-03-21
AU723098B2 (en) 2000-08-17
JP4216905B2 (ja) 2009-01-28
NO990304D0 (no) 1999-01-22
IL127911A0 (en) 1999-11-30
KR20000029548A (ko) 2000-05-25
ATE236904T1 (de) 2003-04-15
CN1251589A (zh) 2000-04-26
EP0915875B1 (en) 2003-04-09
EA199900164A1 (ru) 2000-04-24
SK9399A3 (en) 2000-04-10
WO1998004559A2 (en) 1998-02-05
NZ333768A (en) 2000-09-29
BG103112A (en) 1999-09-30
DE69720732D1 (de) 2003-05-15
EP0915875A2 (en) 1999-05-19
EA002436B1 (ru) 2002-04-25
AU3553997A (en) 1998-02-20
DE69720732T2 (de) 2004-01-29
HUP0600527A2 (en) 2006-11-28
US6255305B1 (en) 2001-07-03
IS4949A (is) 1999-01-19
NO990304L (no) 1999-03-25
JP2002514169A (ja) 2002-05-14
TR199900047T2 (xx) 1999-03-22
PL331072A1 (en) 1999-06-21
BR9710729A (pt) 1999-08-17
CZ18199A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
ES2194205T3 (es) Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
PA8510001A1 (es) Antagonistas del factor liberador de corticotropina
ES2101063T3 (es) Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa.
ES2188793T3 (es) Agente para el tratamiento de las enfermedades neurodegenerativas.
HN2001000192A (es) Derivados de pirazol
ES2076303T3 (es) Derivados de decahidro isoquinoleina, procedimiento para su preparacion y su uso como medicinas.
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2159760T3 (es) Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ES2175386T3 (es) Derivados de 2,3-benzodiazepina y su utilizacion como inhibidores de receptores de ampa.
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
EA200100071A1 (ru) Замещенное производное триазоло-пиридазина, фармацевтические композиции, приготовленные на его основе
ES2149504T3 (es) Imidazo(1,2-a)quinoxalin-4-aminas activas como antagonistas de la adenosina, procedimiento para su preparacion y composiciones farmaceuticas de las mismas.
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
DE69824195D1 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
ES2156889T3 (es) Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos.
ES2162686T3 (es) Nuevos derivados carboxamidas ciclicos sustituidos por carboxi.